Sensible comment. Pardon my ignorance but I could not decipher the GLTAH acronym.
My view of the presentation is that the results are already out there in the form of the released abstract, and that interest will centre on the discussion, as a guide to expert sentiment. Certainly the secondary endpoint trial results have been encouraging. Unfortunately it is the survival data that really counts, and to be statistically significant, we will have to wait until 2017 when the results of the Foxfire trials are available to swell the patient numbers to in excess of 1000.
Sensible comment. Pardon my ignorance but I could not decipher...
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.8¢ |
Change
0.003(1.43%) |
Mkt cap ! $75.34M | |||
| Open | High | Low | Value | Volume |
| 17.8¢ | 17.8¢ | 17.5¢ | $9.047K | 50.98K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 7293686 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 1399496 | 11 |
View Market Depth
| Last trade - 15.01pm 26/07/2024 (20 minute delay) ? |
| SRX (ASX) Chart |